OR WAIT null SECS
© 2021 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
© 2021 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
August 09, 2021
The American Academy of Ophthalmology says biosimilar alternatives to Avastin have never been tested in the eye.
July 21, 2021
Diana Do, MD, and Steven Peskin, MD, MBA, FACP, discuss unmet needs and future approaches to treatment in wet AMD.
Steven Peskin, MD, MBA, FACP, provides insight into managed care considerations of wet AMD including clinical evidence evaluation, formulary management, and value-based agreements.
Diana Do, MD, discusses outcomes of interest for anti-VEGF agents, clinical evidence supporting the treat-and-extend approach, and strategies to overcome financial barriers in wet AMD.
Diana Do, MD, provides insight into anti-VEGF treatment selection for individual patients, evaluation of patient response to therapy, and considerations for switching of agents.
Diana Do, MD, provides an overview of available anti-VEGF agents used in the treatment of wet AMD and Steven Peskin, MD, MBA, FACP, discusses management strategies employed with these agents.
Diana Do, MD, and Steven Peskin, MD, MBA, FACP, discuss overtreatment and undertreatment in wet AMD in addition to the risks associated with delays in therapy.
Steven Peskin, MD, MBA, FACP, discusses drivers of cost and goals of therapy in wet AMD, and Diana Do, MD, discusses the different treatment approaches to the disease.
Diana Do, MD provides an overview of wet age-related macular degeneration including typical clinical manifestations, goals of therapy, and the current treatment landscape.